View on Pubmed.gov 22970722 | View on doi.org 10.1146/annurev...
Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.
- Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA. robert.desnick@mssm.edu
Abstract
In 1964, Christian de Duve first suggested that enzyme replacement might prove therapeutic for lysosomal storage diseases (LSDs). Early efforts identified the major obstacles, including the inability to produce large quantities of the normal enzymes, the lack of animal models for proof-of-concept studies, and the potentially harmful immune responses to the "foreign" normal enzymes. Subsequently, the identification of receptor-mediated targeting of lysosomal enzymes, the cloning and overexpression of human lysosomal genes, and the generation of murine models markedly facilitated the development of enzyme replacement therapy (ERT). However, ERT did not become a reality until the early 1990s, when its safety and effectiveness were demonstrated for the treatment of type 1 Gaucher disease. Today, ERT is approved for six LSDs, and clinical trials with recombinant human enzymes are ongoing in several others. Here, we review the lessons learned from 20 years of experience, with an emphasis on the general principles for effective ERT and the remaining challenges.
References
Cited by 258 citations (total)
Journal Article Review Research Support, N.I.H., Extramural
Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs).
Electronic publication date May 30, 2017
Nihar Kinarivala [...] Paul C Trippier et al.
The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited and incurable neurodegenerative disorders primarily afflicting the pediatric population. Current...
Journal Article Review
Glycan analysis of therapeutic glycoproteins.
Electronic publication date December 15, 2016
Lei Zhang [...] Baolin Zhang et al.
Therapeutic monoclonal antibodies (mAbs) are glycoproteins produced by living cell systems. The glycan moieties attached to the proteins can directly...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •